X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (86) 86
Publication (4) 4
Magazine Article (2) 2
Newsletter (2) 2
Newspaper Article (2) 2
Trade Publication Article (2) 2
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (62) 62
lisinopril (57) 57
lisinopril - therapeutic use (32) 32
male (32) 32
angiotensin-converting enzyme inhibitors - therapeutic use (31) 31
female (28) 28
middle aged (28) 28
hypertension - drug therapy (27) 27
index medicus (22) 22
pharmacology & pharmacy (21) 21
aged (20) 20
angiotensin-converting enzyme inhibitors - economics (18) 18
antihypertensive agents - therapeutic use (18) 18
hypertension (18) 18
lisinopril - economics (18) 18
mortality (15) 15
medicine, general & internal (14) 14
cost-benefit analysis (13) 13
treatment outcome (13) 13
adult (12) 12
angiotensin-converting enzyme inhibitors - administration & dosage (12) 12
enalapril (12) 12
lisinopril - administration & dosage (12) 12
ace inhibitors (11) 11
antihypertensive agents - economics (11) 11
drug therapy (11) 11
heart failure - drug therapy (11) 11
cardiac & cardiovascular systems (10) 10
blood pressure - drug effects (9) 9
blood-pressure (9) 9
captopril (9) 9
antihypertensive agents - administration & dosage (8) 8
prevention (8) 8
retrospective studies (8) 8
risk factors (8) 8
time factors (8) 8
ace-inhibitors (7) 7
amlodipine - therapeutic use (7) 7
analysis (7) 7
antihypertensive drugs (7) 7
drug costs (7) 7
heart failure (7) 7
hydrochlorothiazide (7) 7
hypertension - physiopathology (7) 7
management (7) 7
angiotensin (6) 6
antihypertensive agents - adverse effects (6) 6
blood pressure (6) 6
cardiovascular diseases - prevention & control (6) 6
chlorthalidone - therapeutic use (6) 6
clinical trials as topic (6) 6
converting enzyme-inhibitors (6) 6
dosage and administration (6) 6
drugs (6) 6
hypertension - complications (6) 6
morbidity (6) 6
myocardial-infarction (6) 6
peripheral vascular disease (6) 6
renin-angiotensin system - drug effects (6) 6
amlodipine - economics (5) 5
angiotensin-converting enzyme inhibitors - adverse effects (5) 5
angiotensin-converting enzyme inhibitors - pharmacology (5) 5
chemistry, analytical (5) 5
clinical trials (5) 5
converting-enzyme-inhibitors (5) 5
diuretics (5) 5
diuretics - economics (5) 5
diuretics - therapeutic use (5) 5
double-blind method (5) 5
economics (5) 5
efficacy (5) 5
health care sciences & services (5) 5
lisinopril - adverse effects (5) 5
myocardial infarction - prevention & control (5) 5
tetrazoles - therapeutic use (5) 5
united states (5) 5
ace inhibitor (4) 4
angiotensin-converting enzyme (4) 4
calcium channel blockers - therapeutic use (4) 4
cardiac glycosides (4) 4
cardiotonic agents (4) 4
cardiovascular diseases (4) 4
chlorthalidone - economics (4) 4
congestive-heart-failure (4) 4
diabetes (4) 4
disease (4) 4
disease progression (4) 4
dose-response relationship, drug (4) 4
drug therapy, combination (4) 4
enalapril - therapeutic use (4) 4
enzymes (4) 4
hypertension - economics (4) 4
internal medicine (4) 4
lisinopril - pharmacology (4) 4
medicine & public health (4) 4
methods (4) 4
myocardial infarction - drug therapy (4) 4
perindopril (4) 4
pharmaceutical industry (4) 4
pharmacokinetics (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 12/2002, Volume 288, Issue 23, pp. 2981 - 2997
Journal Article
Journal Article
Renal Failure, ISSN 0886-022X, 2/2013, Volume 35, Issue 1, pp. 23 - 28
Background: The impact of acute kidney injury (AKI) on chronic kidney disease (CKD) progression remains uncertain; the common belief is that AKI in CKD is... 
acute kidney injury | end-stage renal disease | syndrome of rapid-onset end-stage renal disease | economic analysis | renoprevention | Economic analysis | End-stage renal disease | Syndrome of rapid-onset end-stage renal disease | Renoprevention | Acute kidney injury | ORAL SODIUM-PHOSPHATE | RECEPTOR BLOCKERS | ACUTE-RENAL-FAILURE | CKD PATIENTS | STOPPING INHIBITORS | RENIN-ANGIOTENSIN SYSTEM | UROLOGY & NEPHROLOGY | ALDOSTERONE SYSTEM BLOCKADE | CHRONIC KIDNEY-DISEASE | ARTERY STENOSIS | RAAS BLOCKADE | Prognosis | Wisconsin - epidemiology | Humans | Male | Renal Insufficiency, Chronic - complications | Incidence | Dose-Response Relationship, Drug | Lisinopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Renal Insufficiency, Chronic - economics | Acute Kidney Injury - etiology | Nephrology - organization & administration | Lisinopril - administration & dosage | Hospital Charges | Coronary Care Units - economics | Glomerular Filtration Rate | Risk Factors | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Renal Insufficiency, Chronic - physiopathology | Acute Kidney Injury - prevention & control | Disease Progression | Coronary Artery Disease - therapy | Coronary Artery Disease - complications | Creatinine - blood | Aged | Acute Kidney Injury - epidemiology | Research Design | Index Medicus
Journal Article
Journal of General Internal Medicine, ISSN 0884-8734, 5/2008, Volume 23, Issue 5, pp. 509 - 516
To evaluate the cost-effectiveness of first-line treatments for hypertension.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial... 
cost-effectiveness | angiotensin-converting enzyme inhibitors | Medicine & Public Health | calcium channel blockers | Internal Medicine | diuretic | hypertension | Angiotensin-converting enzyme inhibitors | Diuretic | Hypertension | Cost-effectiveness | Calcium channel blockers | MORTALITY | STATES | DIABETES-MELLITUS | WOMEN | MEDICINE, GENERAL & INTERNAL | IMPACT | PREFERENCES | DISEASE | OUTCOMES | HIGH BLOOD-PRESSURE | BURDEN | Quality-Adjusted Life Years | Chlorthalidone - therapeutic use | Diuretics - economics | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Chlorthalidone - economics | Kaplan-Meier Estimate | Lisinopril - economics | Hypertension - drug therapy | Male | Angiotensin-Converting Enzyme Inhibitors - economics | Amlodipine - therapeutic use | Lisinopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Cost-Benefit Analysis | Diuretics - therapeutic use | Female | Myocardial Infarction - prevention & control | Amlodipine - economics | Calcium Channel Blockers - economics | Drugs | Enzymes | Medical societies | Clinical trials | Heart attack | Cardiac glycosides | Prevention | Cardiotonic agents | Diuretics | Antihypertensive drugs | Drug therapy | Cardiology | Public health | Prescription drugs | Health economics | Benefit cost analysis | Original
Journal Article
Journal Article
Racionalʹnaâ Farmakoterapiâ v Kardiologii, ISSN 1819-6446, 01/2016, Volume 5, Issue 4, pp. 45 - 50
Aim. Clinico-economical analysis of arterial hypertension (HT) treatmentMaterial and methods. 78 patients with HT were involved into the study. Patients were... 
arterial hypertension | lisinopril | clinico-economical analysis | amlodipine | hydrochlorothiazide
Journal Article
Hypertension Research, ISSN 0916-9636, 04/2007, Volume 30, Issue 4, pp. 325 - 334
We examined the effects of increasing the recommended initial doses of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers... 
Angiotensin-converting enzyme inhibitors | Hypertension | Diabetic nephropathy | Microalbuminuria | Angiotensin receptor blockers | angiotensin-converting enzyme inhibitors | OXIDATIVE STRESS | LOSARTAN | angiotensin receptor blockers | DUAL BLOCKADE | LISINOPRIL | BLOOD-PRESSURE | microalbuminuria | CONVERTING-ENZYME-INHIBITOR | RENIN-ANGIOTENSIN SYSTEM | NITRIC-OXIDE | PERIPHERAL VASCULAR DISEASE | hypertension | diabetic nephropathy | Diabetic Nephropathies - etiology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Tetrazoles - economics | Diabetic Nephropathies - drug therapy | Hypertension - drug therapy | Male | Benzimidazoles - economics | Thiazepines - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - economics | Angiotensin II Type 1 Receptor Blockers - economics | Dose-Response Relationship, Drug | Albuminuria - physiopathology | Diabetic Nephropathies - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Female | Blood Pressure - drug effects | Blood Pressure - physiology | Drug Therapy, Combination | Diabetes Mellitus, Type 2 - complications | Benzimidazoles - therapeutic use | Thiazepines - economics | Albuminuria - etiology | Creatinine - urine | Hypertension - physiopathology | Albuminuria - drug therapy | Cost-Benefit Analysis | Hypertension - complications | Tetrazoles - therapeutic use | Aged
Journal Article
Journal Article
American Journal of Health-System Pharmacy, ISSN 1079-2082, 03/2006, Volume 63, Issue 5, pp. 411 - 418
Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of exenatide are discussed.... 
Administration | Dosage, Drug interactions | Analgesics and antipyretics | Digoxin | Acetaminophen | Diabetes mellitus | Combined therapy | Cardiac drugs | Angiotensin-converting-enzyme inhibitors | Antidiabetic agents | Blood levels | toxicity | dosage | drug interactions | administration | Lovastatin | diabetes mellitus | TREATED PATIENTS | angiotensin-converting-enzyme inhibitors | lisinopril | antidiabetic agents | GLUCAGON-LIKE PEPTIDE-1 | drugs, availability | GLUCOSE | drugs, body distribution | pharmacokinetics | PHARMACOLOGY & PHARMACY | blood levels | SYNTHETIC EXENDIN-4 | exenatide | combined therapy | injections | GLYCEMIC CONTROL | SULFONYLUREA | mechanism of action | metformin | digoxin | half-life | cardiac drugs | ZUCKER RATS | acetaminophen | excretion | INJECTION | analgesics and antipyretics | metabolism | DIFFERENTIATION | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Hypoglycemic Agents - economics | Venoms - economics | Humans | Peptides - pharmacokinetics | Receptors, Glucagon - metabolism | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - metabolism | Exenatide | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Peptides - economics | Animals | Drug Interactions | Glucagon-Like Peptide-1 Receptor | Venoms - therapeutic use | Venoms - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Peptides - therapeutic use | Venoms - pharmacokinetics
Journal Article